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Abstract
Previous studies on monocarboxylate transporters expression in prostate cancer (PCa) have shown that monocarboxylate transporter 2 (MCT2)
was clearly overexpressed in prostate malignant glands, pointing it out as a putative biomarker for PCa. However, its localization and possible
role in PCa cells remained unclear. In this study, we demonstrate that MCT2 localizes mainly at peroxisomes in PCa cells and is able to take
advantage of the peroxisomal transport machinery by interacting with Pex19. We have also shown an increase in MCT2 expression from non-
malignant to malignant cells that was directly correlated with its peroxisomal localization. Upon analysis of the expression of several peroxi-
somal b-oxidation proteins in PIN lesions and PCa cells from a large variety of human prostate samples, we suggest that MCT2 presence at
peroxisomes is related to an increase in b -oxidation levels which may be crucial for malignant transformation. Our results present novel evi-
dence that may not only contribute to the study of PCa development mechanisms but also pinpoint novel targets for cancer therapy.
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Introduction
Metabolic adaptation is now considered a new hallmark of cancer, in
which cancer cells exhibit high rates of glucose consumption and
consequent lactate production [1]. The crucial role of lactate
exchange within the tumour microenvironment drew attention to
monocarboxylate transporters (MCTs). In glycolytic tumours, they
promote the efflux of lactic acid, being important players in the main-
tenance of the tumour intracellular pH, avoiding the routing to apop-
tosis and providing the favourable microenvironment conditions for
invasion [2–4]. MCTs have been described in a large variety of
tumours and their use as targets for cancer therapy have been widely
suggested. However, the importance of MCTs expression in prostate
cancer (PCa) is still not well understood [5].
Prostate cancer is the second most common malignancy in men,
involving challenging diagnostics [6]. Several proteins, among which
MCT2, have been identified as possible PCa biomarkers [7]. Previous
studies point out to a consistent overexpression of MCT2 in PCa cells
and its possible relevance as a putative biomarker in PCa because of
its high sensitivity and specificity to detect malignant glands. MCT2
protein levels were significantly up-regulated (80–100%) in PCa and
prostatic intraepithelial neoplasia (PIN) lesions in human samples, in
sharp contrast to the near complete lack of expression in both benign
hyperplastic and normal prostate glands. These data suggest a basic
mechanistic role for this protein throughout the early stages of PCa
formation and prompted us to investigate this transporter in more
detail [7]. Similarly to MCT1, MCT2 was also found to localize in mito-
chondria and peroxisomes in non-tumour liver fractions [8–11].
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The presence of MCTs in mitochondria is justified by the need of a
pyruvate carrier that plays a central role in carbohydrate and fat
metabolism. In contrast, the presence of MCT1 and MCT2 at peroxi-
somes was explained as being involved in a lactate–pyruvate shuttle
system present in the membrane of this organelle. This shuttle was
suggested to play an important role in the oxidation of NADH gener-
ated by b-oxidation, being crucial for the maintenance of peroxisomal
viability and, consequently, b-oxidation rates. Although the role of
MCT2 in cancer is not yet elucidated, a recent study showed that
MCT2 knockdown suppressed KRAS mutant (the mutation in KRAS
gene occurs in a big percentage of colorectal cancers and has been
suggested to be associated with proliferation and decreased apopto-
sis in cancer cells) colorectal tumour growth in vivo, supporting the
use of MCT2 as a promising target for inhibition of colorectal cancer
[12]. However, so far, the precise localization and role of MCT2 in
PCa is still unknown.
Importantly, MCT2 staining in PCa was comparable to alpha-meth-
ylacyl-CoA racemase (AMACR), an already established biomarker in
PCa. Under normal physiological conditions, AMACR is expressed at
appreciable levels and is transported to both the peroxisomal and
mitochondrial compartments in a variety of tissues, including liver,
kidney, skeletal muscle, gall bladder and brain [13–16]. AMACR is
responsible for the interconversion of R-configured b-methyl groups
found within various small fatty acid molecules containing branched
chains (such as phytols and bile acids) to the S form, a pre-requisite
for metabolism via the b-oxidation pathway [17, 18]. A similar staining
pattern between MCT2 and this crucial component of the oxidative
metabolism raised the hypothesis that this MCT isoform might also be
involved in these peroxisomal and mitochondrial-dependent mecha-
nisms. In this work, we aimed at unravelling MCT2’s intracellular
localization and expression across prostate malignant transformation
using different models of disease progression.
Our results demonstrate for the first time that MCT2 is pres-
ent at the peroxisomes of PCa cells and that its expression
increases from non-malignant to malignant cells, directly correlat-
ing with its localization at peroxisomes. Using a large series of
human prostate samples, we have also shown an increase in the
expression of peroxisomal b-oxidation proteins in PIN lesions and
PCa cells. Our data provide novel evidence for the importance of
MCT2- and peroxisomal-dependent mechanisms in PCa initiation
in humans.
Material and methods
Cell culture
In this study, we have used several prostate cell lines such as PNT1A
(non-malignant), 22Rv1 (localized tumour) and PC3 (bone metastasis).
Cells were seeded in RPMI-1640 (Gibco, Invitrogen, Carlsbad, CA, USA)
supplemented with 10% of foetal bovine serum (PAA Laboratories
GmbH, C€olbe, Germany), 1% of antibiotic (penicillin/streptomycin) (PAA
Laboratories GmbH) and incubated at 37°C in an atmosphere containing
5% CO2. All cell lines were cultivated under the same experimental con-
ditions and observations were made at about 70% cell confluence.
Antibodies and plasmids
For the immunofluorescence experiments, the following antibodies were
used: MCT2 (sc-14926; Santa Cruz Biotechnology, Santa Cruz, CA, USA),
MCT1 (sc-365501; Santa Cruz Biotechnology), MCT4 (sc-50329; Santa
Cruz Biotechnology), CD147 (sc-71038; Santa Cruz Biotechnology), gp70
(HPA017740, 1:100; Atlas Antibodies, Stockholm, Sweden), PEX14 (a gift
from Dr. Dennis Crane, Griffith University, Brisbane, Australia), catalase
(ab88650; Abcam, Cambridge, UK), TRITC (Jackson ImmunoResearch,
West Grove, PA, USA) and Alexa 488 (Invitrogen, Life Technologies,
Carlsbad, CA, USA). For the Western blot analysis, the following antibod-
ies were used: MCT2, ACOX1 (a gift from A. V€olkl, University of Heidel-
berg, Germany), ACOX3 (sc-135435; Santa Cruz Biotechnology), PEX14,
PMP70 (SAB4200181; Sigma-Aldrich, St Louis, MO, USA) and a-Tubulin
(T9026, Sigma-Aldrich). For the immunohistochemistry (IHC) staining,
the following antibodies were used: AMACR (504R-16, Cell Marque,
Rocklin, CA, USA), ACOX3 (sc-135435; Santa Cruz Biotechnology) and
DBP (a gift from Dr. Gabriele Moller from HelmholtzZentrum
M€unchen). Pex19-YFP plasmid was a gift from Dr M. Schrader, Exeter
University, UK.
Immunofluorescence and microscopy techniques
Immunofluorescence analyses were performed in cells seeded on glass
cover slips that were fixed with 4% paraformaldehyde in PBS, pH 7.4
for 20 min. Afterwards, cells were permeabilized with 0.2% Triton
X-100 for 10 min., blocked with 1% BSA solution for 10 min. and
incubated with primary (MCT2, MCT1, MCT4, CD147, gp70, PEX14,
catalase) and secondary antibodies (TRITC or Alexa488) for 1 hr each.
Between each step, cells were washed three times with PBS, pH 7.4.
Lastly, cells were stained with Hoechst 33258 (PolySciences, Warring-
ton, FL, USA) and mounted in slides using Mowiol 4-88 containing
n-propylgallate. Images were obtained using a Zeiss LSM 510 Meta
Confocal setup (Carl Zeiss, Jena, Germany) equipped with a plan-Apo-
chromat 1009/1.4 oil objective. Quantifications of co-localizations were
performed by determining the Manders’ coefficients using the JACoP
(ImageJ, Bethesda, MD, USA) software.
Cell fractionation
22Rv1 and PC3 cells were collected in PBS with a rubber scraper. Upon
centrifugation at 500 9 g for 5 min., the pellet was homogenized in
homogenization buffer (5 mM MOPS, pH 7.4, 250 mM sucrose, 1 mM
EDTA, protease-inhibitor mixture) and passed gently through a 26-gauge
syringe needle, giving rise to the total homogenate fraction (TH). A part
of this homogenate was centrifuged at 1000 9 g for 10 min. and the
pellet corresponding to nuclei and cellular membranes were discarded.
The supernatant was again centrifuged at 2500 9 g for 15 min. at 4°C
to separate the pellet containing heavy mitochondria. This new superna-
tant was centrifuged at 37,000 9 g for 20 min., giving rise to a peroxi-
some-enriched pellet (which may also contain some degree of light
mitochondria, lysosomes and endosomes) which was gently resus-
pended in homogenization buffer (PF). The supernatant was saved as
cytosol and microsome fraction (CF). Protein concentrations of all frac-
tions were determined by Bradford assay (Bio-Rad, Hercules, CA, USA)
and 60 lg of each was loaded on the gels and subjected to Western
Blot analysis.
724 ª 2015 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
Western Blot
Cells were lysed with specific lysis buffer (25 mM Tris-HCl, pH 8.0,
50 mM sodium chloride, 0.5% sodium deoxycholate, 0.5% Triton X-100
and a protease-inhibitor mix). To improve protein extraction, samples
were passed 20 times through a 26-gauge syringe needle and incubated
on a rotary mixer at for 30 min. at 4°C. After cleared by centrifugation
(17,000 9 g, 15 min.), protein concentrations were determined by
Bradford assay (Bio-Rad). Blots were incubated with the specific pri-
mary antibodies MCT2, MCT1, MCT4, Pex14, PMP70, ACOX1, ACOX3
and a-Tubulin. The antibodies were detected by a horseradish peroxi-
dase-linked secondary antibody (HRP) using an enhanced chemilumi-
nescence system (GE Healthcare, Waukesha, WI, USA).
Immunoprecipitation
22Rv1 cells were transfected with Pex19-YFP using Turbofect in vitro
transfection kit (Thermo Scientific, Marietta, OH, USA) according to
the manufacturer’s instructions. For immunoprecipitation of Pex19-
YFP, the GFP Trap_M (Chromotek, Planegg-Martinsried, Germany) was
used. Transfection with a plasmid containing GFP (GFP-C1) was used
as negative control. After 48 hrs of transfection, cell pellets were incu-
bated in lysis buffer (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.5 mM
EDTA, 0.5% NP-40 and a protease-inhibitor mix). The lysate was
cleared by centrifugation (17,000 9 g, 15 min.) and diluted with dilu-
tion buffer (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.5 mM EDTA
and a protease-inhibitor mix). Protein concentrations were determined
by Bradford assay (Bio-Rad, Hercules, CA, USA). Ice-cold dilution buf-
fer was used to equilibrate beads and the cell lysates were incubated
for 2 hrs at 4°C on a rotary mixer. Beads were washed three times
with dilution buffer and resuspended in 39 SDS sample buffer and
boiled for 10 min. to elute bound proteins. Immunoprecipitated sam-
ples were separated in a 12.5% SDS-polyacrylamide gel and analysed
by Western Blot.
Patients’ samples and tissue microarray
construction
Prostate tissues were obtained from 480 patients with a median age of
64 years old, following radical prostatectomy. Samples, including 203
non-neoplastic, 176 high-grade PIN and 480 neoplastic tissues were used
and organized into tissue microarray blocks (TMAs). The clinico-pathologi-
cal data were assessed for all patients. Haematoxylin and eosin-stained
sections for each tumour were examined by two independent pathologists
and three 2-mm diameter representative cores from the tumour specimens
were cut and placed randomly in TMA recipient blocks. Benign samples
were obtained from 12 patients undergoing radical cystoprostatectomy for
transitional cell carcinoma of the bladder and 10 metastatic PCa cases
were obtained from clinical biopsy samples. The present study was
approved by the Hospitals Local Ethical Review Committees.
Immunohistochemistry staining and analysis
Formalin-fixed paraffin-embedded 4-lm sections were prepared from
the TMA blocks. IHC technique was performed according to avidin–
biotin–peroxidase complex principle [R.T.U Vectastain Elite ABC Kit
(Universal), Vector Laboratories, Burlingame, CA, USA)], with the
primary antibodies for AMACR (504R-16, Cell Marque), ACOX-3
(sc-135435; Santa Cruz Biotechnology) and DBP (a gift from Dr.
Gabriele Moller from HelmholtzZentrum, Munich). IHC evaluation was
performed blindly by two independent observers that assessed the
intensity and the extension of the staining, as previously described [5].
Results
MCT2 localizes at peroxisomes in PCa cells
To access the exact intracellular localization of MCT2 in PCa cells, we
have performed immunolocalization analyses of MCT2 in different cel-
lular models of PCa disease progression: PNT1A (non tumour),
22Rv1 and PC3. As McClelland et al. (2003) have shown a peroxi-
somal localization of MCT2 in non-tumour liver fractions, we firstly
tested whether this protein would as well be present in this organelle
in PCa cells. To that end, the localization of MCT2 was analysed in
parallel with the peroxisomal marker catalase.
Our results have interestingly demonstrated that, although no co-
localization was observed between MCT2 and the peroxisomal marker
in PNT1A, this protein is localized at peroxisomes in all the malignant
cell lines (Fig. 1). We have, however, observed that the localization
level varied across the different models. In 22Rv1 cells, MCT2 was
mainly found at peroxisomes with a minor portion spread throughout
the cytoplasm as small aggregates (Fig. 1A d–f). Quantification analy-
ses show that 60.35% of the MCT2 co-localizes with the peroxisomal
marker. However, the ratio of peroxisomal MCT2/cytoplasmic MCT2
decreased with disease progression, culminating with 34% of MCT2
at peroxisomes in PC3 cells (Fig. 1A g–i).
To substantiate these results, we have performed differential cen-
trifugation analyses with lysates from 22Rv1 and PC3 cells and
obtained a fraction that (although presenting some degree of contam-
ination with light mitochondria and small vesicles such as lysosomes
and endosomes) is highly enriched in peroxisomes (Fig. 1B, PF). The
results (Fig. 1B) clearly show that MCT2 localizes at the peroxisome-
enriched fractions in both cell lines. Surprisingly, the amount of
MCT2 at peroxisomes appears to correlate with a change on the orga-
nelle’s morphology. In fact, in cells where no MCT2 was present at
peroxisomes (PNT1A), this organelle exhibits a regular phenotype
(with 67.7% round and 32.3% tubular; Fig. 1A a–c). Curiously, in
22Rv1 cells (where MCT2 was mainly observed at peroxisomes), this
organelle appears somewhat elongated and in clusters (with only
15.6% round and 84.4% tubular and in clusters). In PC3, the highly
metastatic model, peroxisomes appear similar to ones in the non-
malignant cells PNT1A (with 73.1% round and 26.9% tubular; Fig. 1A
g–i). Further experiments will have to be performed to better analyse
the correlation between MCT2 localization at the peroxisomes and the
different organelle morphologies.
Strikingly, the expression level of MCT2 increases from non-
tumour (PNT1A) to localized malignant cells (22Rv1) in about 784%
correlating to its change in localization from cytoplasmic to peroxi-
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somal (Fig. 1C). An increase in expression level (of about 89%) was
also observed for Pex14 (a peroxisomal membrane protein; Fig. 1D),
suggesting an increase in peroxisomal membrane surface/number
accompanying the malignant transformation.
Other MCT isoforms are present at the
peroxisomes, plasma membrane, cytoplasm and
nucleus of PCa cells
As McClelland et al. (2003) have also shown a peroxisomal localiza-
tion of MCT1 in non-tumour liver fractions, we decided to test whether
this protein would also be present in this organelle in PCa cells.
Upon immunolocalization of MCT1 together with peroxisomal
markers, we have observed a small degree of co-localization with
the peroxisomal marker (Fig. 2A) in the tumour cell lines (5.15% of
the MCT2 co-localizes with the peroxisomal marker in 22RV1 cells
and 4% in PC3 cells). Differential centrifugation analyses with ly-
sates from 22Rv1 and PC3 cells (Fig. 2B) clearly confirm that
MCT1 localizes at the peroxisome-enriched fractions in both cell
lines.
However, MCT1 was mainly found to strongly localize at the
nucleus in all cell lines (Fig. 2A) and was also present at the cyto-
plasm and plasma membrane (Fig. 2A). The expression level of MCT1
increased from the PNT1A cells to the tumour cell lines, with a higher
expression at PC3 cells then at 22RV1 cells (Fig. 2C).
A
B
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Fig. 1MCT2 localizes at peroxisomes in
PCa cells. (A) a–c: MCT2 intracellular
localization in PNT1A cells, (a) MCT2, (b)
catalase and (c) merge image of a and b;
d–f: MCT2 intracellular localization in
22RV1 cells, (d) MCT2, (e) catalase and
(f) merge image of d and e; g–i: MCT2
intracellular localization in PC3 cells, (g)
MCT2, (h) catalase and (i) merge image
of g and h. Arrows indicate some of the
co-localization sites. Nuclei are shown in
blue (stained with Hoechst 33258). Bars
represent 5 lm. (B) Western blot analysis
of the presence of MCT2 in peroxisomal-
enriched (PF) and cytosolic and micro-
somal (CF) subcellular fraction of 22Rv1
and PC3 cells upon differential centrifuga-
tion. TH represents total homogenate.
PMP70 and a-tubulin are used as peroxi-
some and cytosol markers, respectively.
(C) Western blot analysis showing the lev-
els of MCT2 in the different prostate cell
lines models, PNT1A, 22RV1 and PC3. (D)
Western blot analysis showing the levels
of Pex14 in the different prostate cell lines
models, PNT1A, 22RV1 and PC3.
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Interestingly, MCT1 chaperone CD147 was found to localize not
only at the plasma membrane and cytoplasm but also at the nuclear
envelope, mainly in 22RV1 cells (Fig. 3).
As the intracellular localization of MCT4 in PCa cells has never
been assessed, we have also analysed it by immunolocalization with
organelle markers. MCT4 was found mainly at the cytoplasm in all the
three cell lines with some degree of localization at the peroxisomes
(6.78% of the MCT4 co-localizes with the peroxisomal marker in
22RV1 cells and 4.77% in PC3 cells). In PC3 cells, however, a strong
plasma membrane staining was also observed (Fig. 4A). The peroxi-
somal localization in both 22Rv1 and PC3 cells was confirmed by dif-
ferential centrifugation analyses (Fig. 4B). The expression level of
MCT4 is similar in PNT1A and PC3 cells, decreasing in 22Rv1 cells
(Fig. 4C).
MCT2 travels to the peroxisomal membranes via
interaction with PEX19
The quick movement of monocarboxylates across the membranes is
imperative for cellular metabolism. These proteins are thought to
require chaperones such as CD147 in the case of MCT1 and MCT4, or
gp70 in the case of MCT2, for appropriate expression and activity in
the plasma membrane. As MCT2 was the main isoform found to
strongly localize at peroxisomes in PCa cells, we aimed at better
unravelling its targeting mechanism to this organelle. A previous
study was unable to find gp70 expression in human prostate samples
that exhibited MCT2 expression [5]. However, our studies with confo-
cal microscopy allowed us to observe some, although scarce, gp70
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Fig. 2MCT1 localizes at peroxisomes,
cytoplasm, nucleus and plasma membrane
in PCa cells. (A) a–c: MCT1 intracellular
localization in PNT1A cells, (a) MCT1, (b)
Pex14 and (c) merge image of a and b;
d–f: MCT1 intracellular localization in
22RV1 cells, (d) MCT1, (e) Pex14 and (f)
merge image of d and e; g–i: MCT1 intra-
cellular localization in PC3 cells, (g)
MCT1, (h) Pex14 and (i) merge image of
g and h. Arrows indicate some of the co-
localization sites. Nuclei are shown in blue
(stained with Hoechst 33258). Bars repre-
sent 5 lm. (B) Western blot analysis of
the presence of MCT1 in peroxisomal-
enriched (PF) and cytosolic and micro-
somal (CF) subcellular fraction of 22Rv1
and PC3 cells upon differential centrifuga-
tion. TH represents total homogenate.
PMP70 and a-tubulin are used as peroxi-
some and cytosol markers, respectively.
(C) Western blot analysis showing the lev-
els of MCT1 in the different prostate cell
lines models, PNT1A, 22RV1 and PC3.
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distributed in the cytoplasm without any co-localization with peroxi-
somal markers (results not shown). Hence, the protein that actually
behaves as chaperone for MCT2’s transport to peroxisomes in
prostate cells remained unknown.
As Pex19 is the main responsible for the transport of peroxisomal
membrane proteins to this organelle [19, 20], we tested whether this
protein could act as a chaperone for MCT2 in these cells. As in
22RV1, the majority MCT2 was present at peroxisomes, it was the
chosen model to study the possible interaction between MCT2 and
PEX19. 22RV1 cells transfected with Pex19-YFP were then subject to
immunoprecipitation experiments. Our results showed, indeed, an
interaction between MCT2 and PEX19 (Fig. 5), suggesting that MCT2
is able to take advantage of peroxisomal transport machinery to reach
this organelle.
The expression of MCT2 and peroxisomal
b-oxidation-related proteins increase in prostate
malignant transformation
McClelland et al. (2003) observed a decrease in b-oxidation upon
MCTs inhibition, suggesting that the presence of MCT2 at peroxi-
somes of non-malignant liver cells would be essential for the mainte-
nance of peroxisomal viability and consequently b-oxidation rates.
Hence, we hypothesized that the increase in MCT2 expression from
non-malignant prostate cells (PNT1A) to localized prostate tumour
cells (22RV1) could be related with an increase in peroxisomal b-oxi-
dation. In fact, we observed an increase in the expression levels of
ACOX1 (of about 246%; Fig. 6A) and ACOX3 (about 14%; Fig. 6B),
two central proteins in the peroxisomal b-oxidation pathway [18, 21,
22]. These results interestingly suggest that, indeed, the increase in
MCT2 expression levels as well as its presence at peroxisomes, are
related to an increase in b-oxidation levels which may be crucial for
malignant transformation. Further experiments need to be performed
to confirm this correlation.
Peroxisome-related proteins are overexpressed
in human PCa samples
To study the pathological relevance of the expression of proteins
involved in peroxisomal b-oxidation in human samples, we charac-
terized the expression of AMACR, ACOX3 and DBP in a large series
of human prostate samples. Figure 7 shows representative immu-
nohistochemical reactions for all proteins in BT (benign tissue), PIN
lesions, primary tumour tissue (TT) and metastatic tissue (MT). We
observed important changes in the expression of all the proteins
studied from benign and/or adjacent non-neoplastic prostate tissue
to PIN lesions and to primary tumour. AMACR, ACOX3 and DBP
expressions was clearly increased from BT to TT. Figure 8A shows
A B C
D E F
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Fig. 3 CD147 localizes at the cytoplasm,
nuclear and plasma membranes in PCa
cells. A–C: CD147 intracellular localization
in PNT1A cells, (A) CD147, (B) Pex14 and
(C) merge image of A and B; D–F: CD147
intracellular localization in 22RV1 cells,
(D) CD147, (E) Pex14 and (f) merge
image of D and E; G–I: CD147 intracellular
localization in PC3 cells, (G) CD147, (H)
Pex14 and (I) merge image of G and H.
Nuclei are shown in blue (stained with
Hoechst 33258). Bars represent 5 lm.
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the specific percentage of positive cases for each protein in differ-
ent tissues. Interestingly, an evident increase was verified from BT
or NNT to PIN and TT. In Figure 8B and C, the distribution of the
final score across different prostate tissue types for each protein is
represented, showing in a general way that there is an increase in
the final score in the localized tumour when compared to the benign
glands.
Discussion
A variety of studies pointed to the importance of MCTs in solid
tumours. In contrast to MCT1 and MCT4, which were mainly
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Fig. 4MCT4 localizes at peroxisomes,
cytoplasm and plasma membrane in PCa
cells. (A) a–c: MCT4 intracellular localiza-
tion in PNT1A cells, (a) MCT4, (b) cata-
lase and (c) merge image of a and b; d–f:
MCT4 intracellular localization in 22RV1
cells, (d) MCT4, (e) catalase and (f)
merge image of d and e; g–i: MCT4 intra-
cellular localization in PC3 cells, (g)
MCT4, (h) catalase and (i) merge image
of a and g and h. Arrows indicate some of
the co-localization sites. Nuclei are shown
in blue (stained with Hoechst 33258).
Bars represent 5 lm. (B) Western blot
analysis of the presence of MCT4 in per-
oxisomal-enriched (PF) and cytosolic and
microsomal (CF) subcellular fraction of
22Rv1 and PC3 cells upon differential cen-
trifugation. TH represents total homoge-
nate. PMP70 and a-tubulin are used as
peroxisome and cytosol markers, respec-
tively. (C) Western blot analysis showing
the levels of MCT4 in the different pros-
tate cell lines models, PNT1A, 22RV1 and
PC3.
Fig. 5MCT2 interacts with Pex19. Co-immunoprecipitation analysis of
the interaction between endogenous MCT2 and overexpressed Pex19
(Pex19-YFP) in 22RV1 cells. Negative controls were performed by im-
munoprecipitating cells expressing GFP (GFP-C1). Western blots were
performed with an antibody anti-MCT2. L represents lysate, IP repre-
sents the immunoprecipitation result and S represents the supernatant.
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described at the plasma membrane in a wide variety of malignancies,
MCT2 expression in human cancers was always less evident and,
when present, its expression was mainly cytoplasmic [23]. As so, and
because of the major role described for MCTs as important players in
the acid-resistant phenotype of tumour cells, MCT1 and MCT4 turned
into the most popular isoforms explored for cancer therapy. However,
a study in malignant gliomas and more recently a study in colorectal
malignancies showed a significant role for MCT2 in cancer, describing
that MCT2 inhibition induces senescence-associated mitochondrial
dysfunction and suppresses progression of colorectal malignancies
in vivo [12, 24]. Similarly to what was described for colon cancer,
MCT2 expression in PCa was also observed in the cytoplasm of
tumour cells [7]. The observation that MCT2 was clearly expressed in
PIN lesions and prostate tumour cells strongly pointed into an unex-
plored role of this isoform in prostate malignant transformation.
In this study, we have demonstrated for the first time that MCT2
is localized at peroxisomes in PCa cells. Importantly, its localization
pattern changes across the different in vitro models of prostate dis-
ease progression: while no peroxisomal localization was observed in
non-malignant prostate cells, the highest co-localization level was
detected in the localized tumour cells, decreasing with the level of me-
a b c
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Fig. 7 The expression of proteins involved
in peroxisomal b-oxidation is more
intense in PIN lesions and prostate
tumour samples. Immunohistochemical
expression of metabolic-related proteins in
benign tissue (BT), PIN lesions (PIN),
prostate tumour tissue (TT) and meta-
static tissue (MT; 2009 magnification).
Images are shown with a magnification of
2009.
A B
Fig. 6 Peroxisomal b-oxidation proteins are overexpressed in localized
prostate tumour cells. (A) Western blot analysis, showing the expres-
sion levels of ACOX1 in 22RV1 cells. (B) Western blot analysis, showing
the expression levels of ACOX3 in 22 RV1 cells.
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tastization. These results strongly suggest that the localization of
MCT2 in PCa peroxisomes is important in disease initiation.
Peroxisomes are ubiquitous and essential subcellular organelles,
versatile and highly diverse depending on the organism, cell type and
developmental stage [22, 25–27]. They fulfil important functions in
lipid and reactive oxygen species metabolism, influencing, among
others, neuronal development and ageing [22, 25–27]. The protein
composition, morphology and abundance of these dynamic organelles
are tightly regulated upon external stimuli to maintain cellular homoeo-
stasis [22, 25–27]. Peroxisome dynamics and morphology play
important roles in cell pathology, and defects on these machineries
lead to significant implications in health and disease [26]. Information
on the role of peroxisomes in tumour development is scarce. In some
studies, mainly on hepatocarcinomas, a decrease in peroxisome num-
ber in cancer cells was demonstrated by the reduction in peroxisomal
catalase and the three peroxisomal b-oxidation enzymes [28].
The presence of MCT2 in peroxisomes (in non-tumour liver cells)
was firstly suggested by McClelland et al. (2003) who proposed that
this protein would be involved in a redox shuttle system at the peroxi-
somal membrane, consisting of a substrate cycle between lactate and
pyruvate. This shuttle would stimulate the reoxidation of NADH,
fuelling the organelles very long-chain fatty acid b-oxidation and play-
ing a role in peroxisomal redox balance (McClelland et al., 2003). Our
results seem to highlight a similar role for MCT2 at the peroxisomal
membrane of PCa cells. In parallel to a clear increase on MCT2
expression from non-tumour to localized tumour cells, we have also
observed a rise in the expression of specific key proteins involved in
peroxisomal b-oxidation: ACOX1 and ACOX3. These results suggest
that the presence of MCT2 at peroxisomes stimulates an increase in
the b-oxidation rate that seems to be related with prostate tumour
initiation. Importantly, these results are substantiated by the study of
the expression of AMACR, ACOX3 and DBP in human prostate sam-
ples, showing a specific and consistent overexpression of proteins
involved in peroxisomal fatty acid oxidation in PCa as well as in PIN
lesions in contrast to benign tissue, suggesting a possible aetiological
role for this pathway in malignant transformation.
The observation that the expression level of MCT2 as well as its
co-localization with peroxisomes decreases from the localized tumour
cells to the highly metastatic models likely demonstrates that in these
cells other metabolic mechanisms play a more important role, such
as hypoxia and hypoxic-related proteins involved in glycolysis, which
was already suggested to be linked with disease aggressiveness [29].
To better unravel the mechanisms involved in the peroxisomal and
MCT2-dependent disease initiation, we have analysed the cellular
trafficking of MCT2 and demonstrated that GP70, the previously
described MCT2 chaperone, is barely expressed in the PCa cells, indi-
A B
C D
Fig. 8 The percentage of cases showing increase AMACR, ACOX3 and DBP expression increases in PIN lesions and tumour samples. (A) Overall
percentage of positive cases for each one of the proteins studied in the different tissue samples. (B–D) Distribution of the final staining score for
AMACR (B), ACOX3 (C) and DBP (D) in different PCa tissues.
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cating that MCT2 should rely on an alternative chaperone for its
proper function in these cells. Our results show that MCT2 interacts
with Pex19, the main responsible for the trafficking of intrinsic peroxi-
somal membrane proteins to this organelle. These data strongly
suggest a highjack of the peroxisomal transport machinery to sustain
malignant transformation. We have furthermore observed a clear
change in peroxisome morphology across prostate malignant
transformation correlated with MCT2 presence at this organelle, pro-
viding once more evidence for the involvement of these organelles in
tumour initiation and progression.
In this study, we have also analysed the intracellular localiza-
tion of MCT1 and MCT4 in PCa cells. Surprisingly, both proteins
are also found at peroxisomes, although in a much lower extent
than MCT2. It is tempting to suggest that both MCT1 and MCT4
would be present at the peroxisomal membranes as a partner for
MCT2 within the substrate shuttle. In fact, McCleeland et al.
(2003) have already shown MCT1 to be present in liver peroxi-
somes and to form, along with peroxisomal lactate dehydroge-
nase, a peroxisomal lactate shuttle. However, our results show
that the amount of MCT1 at peroxisomes is much lower than the
one of MCT2. Furthermore, MCT1 is also present at the plasma
membrane and, surprisingly, at the nucleus. Its chaperone CD147
was found to localize at the nuclear membrane, suggesting that it
was the responsible for the MCT1 transport to the nuclear
membrane prior to its internalization. A nuclear localization for
MCT1 has already been shown to occur in human sarcomas [30].
Also, only a small part of MCT4 was found at peroxisomes with
its majority localizing in the cytoplasm and at the plasma mem-
brane, as expected. Although the possibility of MCT1 and/or MCT4
behaving as partners of MCT2 at the peroxisomal membrane is
very appealing, further experiments have to be performed to test
this or other hypothesis concerning their role at this organelle.
Nevertheless, our results suggest that the presence of multiple
MCTs is physiologically important in cancer cells and the involve-
ment of these isoforms in the biology of tumour cells goes
beyond their classical role in the glycolytic metabolism.
Our study describes for the first time the presence of MCT2 at the
peroxisomes of PCa cells and suggests a possible role for peroxi-
some-related mechanisms in prostate malignant transformation.
These results may further be exploited for the study of peroxisomal
metabolism as target for cancer therapy.
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